Literature DB >> 6124219

Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs.

T Takagi, M Takeda, H Maeno.   

Abstract

The inhibitory effect of a new H2-receptor antagonist YM-11170 on gastric acid response to histamine and food was compared with that of cimetidine in the conscious dog with a Heidenhain pouch. When given intravenously at a steady state of gastric secretion by continuous infusion of histamine. YM-11170 was 42 times more potent and 1.3 times longer-lasting (p less than 0.05) than cimetidine in reducing the total acid output. The higher potency of YM-11170 than that of cimetidine was also demonstrated in oral antisecretory tests with histamine. The oral ED50 relative to i.v. ED50 as an indirect indication of absorption rate of the drugs was 2.9 for YM-11170 and 2.7 for cimetidine. The secretory response to food stimulation was also antagonized by oral administration of YM-11170 with 40 times greater potency than that of cimetidine. The antisecretory effects of the drugs on the histamine-induced gastric secretion were characterized by a marked decrease in the secretory volume. No behavioral change was observed in association with the H2-blockers. These results indicate that YM-11170 is a very potent inhibitor of gastric acid secretion and also suggest that the absorption rate of YM-11170 from the gastro-intestinal tract is similar to that of cimetidine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124219

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  13 in total

1.  Does H2-receptor antagonist alter the renal function of cyclosporine-treated kidney grafts?

Authors:  S Inoue; H Sugimoto; T Nagao; N Akiyama
Journal:  Jpn J Surg       Date:  1990-09

Review 2.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Comparative effects of famotidine and cimetidine on 7-ethoxycoumarin O-deethylase activity in human livers.

Authors:  Y Imai; M Inada; S Tamura; S Kawata; Y Minami; S Tarui
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

4.  Effect of H2-receptor antagonists, cimetidine and YM-11170, on serum gastrin levels in lumen-perfused rats.

Authors:  K Ohe; M Nakamura; T Fujiwara; H Matsumoto; M Kohchi; A Miyoshi
Journal:  Dig Dis Sci       Date:  1983-11       Impact factor: 3.199

5.  Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers.

Authors:  C Staiger; B Korodnay; J X Devries; E Weber; P Müller; B Simon; H G Dammann
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

6.  MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect.

Authors:  R W McCallum; A N Chremos; B Kuljian; M A Tupy-Visich; P B Huber
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Gastric acid inhibits antral phase III activity in duodenal ulcer patients.

Authors:  M Kusano; T Sekiguchi; T Nishioka; O Kawamura; K Kikuchi; T Matsuzaki; T Horikoshi
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

9.  Inhibitory effect of famotidine on cat gastric secretion.

Authors:  G Coruzzi; G Bertaccini; M T Noci; G Dobrilla
Journal:  Agents Actions       Date:  1986-11

10.  Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.

Authors:  C Scarpignato; R Tramacere; L Zappia
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.